Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HMGCR | P04035 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31314518 | 1.00 | HTT (0.62) | HTTCYP3A4LCKFYNKDM4E | |
| SCHEMBL2848241 | 0.90 | HTT (0.50) | HTTCYP3A4KDM4ERAB9ALMNA | |
| SCHEMBL1498783 | 0.86 | HTT (0.61) | HTTCYP3A4KDM4ERAB9ALMNA | |
| SCHEMBL13927530 | 0.86 | HTT (0.47) | HTTCYP3A4KDM4ERAB9ALMNA | |
| SCHEMBL22222472 | 0.85 | HTT (0.46) | HTTCYP3A4KDM4ERAB9ALMNA | |
| SCHEMBL9958729 | 0.85 | HTT (0.46) | HTTCYP3A4LCKFYNRAB9A | |
| SCHEMBL6719734 | 0.85 | NPC1 (0.51) | HTTCYP3A4KDM4ERAB9ALMNA | |
| SCHEMBL7891214 | 0.85 | HTT (0.50) | HTTCYP3A4LCKFYNRAB9A | |
| SCHEMBL1766160 | 0.83 | LCK (0.60) | HTTCYP3A4LCKFYNKDM4E | |
| SCHEMBL20780495 | 0.82 | HTT (0.43) | HTTCYP3A4RAB9ALMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210276999-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2021-09-09 | — | — | US | disclosed |
| US-10851101-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3406252-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-3406252-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| EP-2812004-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2018-04-19 | — | — | US | disclosed |
| US-9879007-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| WO-2017161093-A1 | CAFFEIC ACID DERIVATIVES AND USES THEREOF | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2015-01-01 | — | — | US | disclosed |
| EP-2812004-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013119916-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| US-6703387-B2 | STYRYLBENZODIAZEPINES | HOFFMANN-LA ROCHE INC. | 2004-03-09 | — | — | US | disclosed |
| EP-1299364-A1 | BENZODIAZEPINES AS INHIBITORS OF HPV E1 HELICASE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-09 | — | — | EP | disclosed |
| US-20020128262-A1 | Inhibitors of HPV E1 helicase enzyme | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2002-09-12 | — | — | US | disclosed |
| WO-2002000632-A1 | BENZODIAZEPINES AS INHIBITORS OF HPV E1 HELICASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-03 | — | — | WO | disclosed |
| EP-0481441-B1 | Novel cephem compounds, their preparation processes and antibacterial agents | KYORIN SEIYAKU KK (JP) | 1996-12-11 | — | — | EP | disclosed |
| US-5244892-A | Pseudomonas | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0481441-A2 | Novel cephem compounds, their preparation processes and antibacterial agents | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | HTT 755/4885CYP3A4 4757/4885LCK 4832/4885 |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | HTT 264/4885CYP3A4 4809/4885LCK 4802/4885 |
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | HTT 264/4885CYP3A4 4809/4885LCK 4802/4885 |
| US-20210276999-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | HTT 755/4885CYP3A4 4757/4885LCK 4832/4885 |
| US-10851101-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | HTT 755/4885CYP3A4 4757/4885LCK 4832/4885 |
| US-20020128262-A1 | Inhibitors of HPV E1 helicase enzyme | DHX15, DHX35, DHX36 | HTT 1190/4885CYP3A4 328/4885LCK 4521/4885 |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | HTT 577/4885CYP3A4 4323/4885LCK 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.